Oblique Posterior Atraumatic Lumbar (OPAL) System, Polymeric spinal fusion cage, non-sterile, OPA...
FDA Device Recall #Z-1392-2016 — Class II — February 18, 2016
Recall Summary
| Recall Number | Z-1392-2016 |
| Classification | Class II — Moderate risk |
| Date Initiated | February 18, 2016 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Synthes (USA) Products LLC |
| Location | West Chester, PA |
| Product Type | Devices |
| Quantity | 6 units |
Product Description
Oblique Posterior Atraumatic Lumbar (OPAL) System, Polymeric spinal fusion cage, non-sterile, OPAL Spacer 10 mm x 24 mm, 11 mm Height - Revolve Product Usage - The OPAL Spacer is indicated for use in patients with degenerative disc disease (DDD) at one or two contiguous levels from L2 to S1 whose condition requires the use of interbody fusion combined with supplemental fixation. The interior of the OPAL Spacer should be packed with autogenous bone graft (i.e. autograft). DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies. These patients should be skeletally mature and have had six months or non-operative treatment. The OPAL Spacer is intended to be used with Synthes supplemental fixation, e.g. TSLP, ATB, Antegra, Pangea, USS Including ClickX) and small stature USS.
Reason for Recall
The label on the outer packaging does not match the product inside and intended use of the device.
Distribution Pattern
Distributed in the US: OH and ND
Lot / Code Information
Lot # 9984134, Catalog ID 08.803.051, OPAL Spacer 10 mm x 24 mm, 11 mm Height - Revolve
Other Recalls from Synthes (USA) Products LLC
| Recall # | Classification | Product | Date |
|---|---|---|---|
| Z-0228-2026 | Class II | LOW PROF LCKNG SCREW, F/IM NAIL 5.0MM / L, 46MM... | Sep 26, 2025 |
| Z-0229-2026 | Class II | LOW PROF LCKNG SCREW, F/IM NAIL 5.0MM / L, 42MM... | Sep 26, 2025 |
| Z-1916-2024 | Class II | STARDRIVE SCRWDRVR SHFT/T4 50MM/SELF-RETAINING/... | Apr 25, 2024 |
| Z-1239-2024 | Class II | TFNA Femoral Nail 9mm, right, 130¿, L 235mm-In... | Jan 24, 2024 |
| Z-1238-2024 | Class II | RAPIDSORB IPS Battery Pack, Sterile-Intended fo... | Jan 24, 2024 |
Frequently Asked Questions
Contact your healthcare provider and the device manufacturer immediately. Check whether your specific model number and lot number are included in the recall scope. For external devices, stop using the affected product and arrange a replacement. For implanted devices, do not panic — removal is typically not required unless the risk assessment clearly indicates it. Your physician will guide you based on your individual clinical situation and the FDA's recommended actions. Report any adverse effects you may have experienced to FDA MedWatch at 1-800-FDA-1088.
Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.
Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.
What Should You Do?
Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.